On September 18, Novartis AG (NYSE:NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab) to treat polymyalgia rheumatica (PMR) in adults who respond inadequately to steroids or relapse during tapering.
Following this recommendation, the European Commission is expected to issue a final decision within two months. If approved, Cosentyx will become the first IL-17A inhibitor licensed in Europe for PMR, expanding its multi-billion-dollar immunology franchise into a new rheumatologic indication with high unmet demand.
You May Also Want To Read: Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
Expansion in Priority Brands Strengthens Growth Outlook
For bullish investors, the CHMP positive opinion reinforces Novartis’s strategy to drive top-line expansion through its priority brand portfolio. Cosentyx is already an established growth driver alongside brands like Kisqali (+43% cc in Q2 2026), Kesimpta (+32% cc), and Scemblix (+89% cc). Extending Cosentyx into PMR broadens its addressable market, helping to maximize commercial returns on a drug that underpins the company’s baseline commercial traction.
Crucially, commercial expansion directly supports Novartis AG’s strong profitability and cash generation. In Q2 2026, Novartis delivered $14.4 billion in net sales (+3% USD) and generated a core operating income margin of 41.2%, yielding $5.6 billion in quarterly free cash flow ($8.9 billion in H1 2026). This robust organic cash generation is essential: it gives Novartis the necessary liquidity to continue returning capital to shareholders, such as executing its $10 billion share buyback program, while simultaneously funding R&D innovations like its recent pipeline advancements in multiple sclerosis (Remibrutinib) and rare neuromuscular diseases.
Generic Pressures and Leverage Present Commercial Execution Risks
For bearish investors, line extensions like PMR carry execution burdens while failing to completely insulate Novartis from near-term top-line erosion. Generic competition remains a severe drag on financials, subtracting 14 percentage points from Q2 2026 net sales growth and contributing to a 2% decline in operating income (-3% cc). As mature products face patent cliffs, new indications must achieve immediate market adoption to replace lost revenue and protect operating margins.
At the same time, Novartis faces reduced financial flexibility due to a sharp increase in balance sheet leverage. Net debt surged to $39.4 billion as of June 30, 2026, up from $21.9 billion at year-end 2025, largely driven by $15.3 billion in net cash outflows for M&A and asset acquisitions alongside $3.1 billion in treasury share transactions. Higher leverage increases interest obligations, which already pressured Q2 net income (-19%), making Novartis more sensitive to clinical setbacks or slower-than-expected commercial rollouts.
Don’t Miss: Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone
Conclusion
The CHMP recommendation provides a clear regulatory milestone for Novartis AG, unlocking a potential European label expansion that deepens its immunology footprint. While generic headwind pressures and elevated debt levels necessitate disciplined execution, Cosentyx’s pipeline momentum aligns directly with management’s reaffirmed full-year 2026 guidance, offering steady fundamental support for long-term investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Hedge Fund Resource Center